Embecta (EMBC) Q4 2025 earnings summary

Executive summary

• Achieved key milestones in FY25, including ending the Patch Pump Program, executing a restructuring plan, completing ERP and distribution network implementations, and advancing the global brand transition, with 95%+ of North American revenue transitioned to the new brand.

• Advanced GLP-1 strategy with 30+ pharma partners for pen needle co-packaging, with commercial launches expected in Canada, Brazil, and India in 2026.

• Generated $182.4M in free cash flow and paid down $184.5M in debt, exceeding targets and reducing leverage to 2.9x net debt/adjusted EBITDA.

• Exceeded FY25 guidance for adjusted gross margin, operating margin, and EBITDA margin; adjusted EPS at the top end of guidance.

• Initiated the second phase of the strategic roadmap focused on growth, operational efficiency, and accelerated debt reduction.

Financial highlights

• Q4 FY25 revenue: $264M, down 7.7% YoY as reported, or 10.4% on adjusted cost/currency basis.

• Q4 U.S. revenue: $142M, down 15.2% YoY (adjusted); international Q4 revenue: $122M, up 2.8% reported, down 4% adjusted.

• Q4 adjusted gross profit: $159.5M (60.6% margin), down from $178.3M (61.4%) YoY.

• Q4 adjusted operating income: $66.7M (25.3% margin), up from $61.2M (21.1%) YoY.

• Q4 adjusted net income: $29.4M ($0.50/share), up from $25.9M ($0.45/share) YoY.

• FY25 adjusted revenue: $1.08B, down 3.9% YoY (adjusted); adjusted EBITDA: $415.3M (38.5% margin), up from $353.4M (31.4%).

• FY25 adjusted net income: $173.9M ($2.95/share), up from $143.1M ($2.45/share) YoY.

• FY25 free cash flow: $182.4M, up from $19.9M in FY24.

Outlook and guidance

• FY26 adjusted revenue expected flat to down 2% YoY; as-reported revenue guidance: $1,071M–$1,093M.

• Adjusted operating margin guidance: 29%–30%, down ~180 bps at midpoint vs. FY25, mainly due to higher cannula costs and increased R&D.

• Adjusted EPS guidance: $2.80–$3.00, assuming $150M debt repayment and 23% tax rate.

• Free cash flow guidance: $180M–$200M, with $20M capex and $30M one-time spend for global brand transition.

• FY26–FY28: core injection and contract manufacturing revenue CAGR expected to decline 1–2%, offset by new product streams; adjusted operating margin to remain ~28–30%.